This is a golden age of healthcare innovation. Breakthrough products and therapies are extending life, improving delivery of care, and shrinking costs. It continues to be a big opportunity for wise investors who understand this space.
SightLine invests in select, high-potential healthcare companies to unlock value others can’t. Through custom financing solutions and active management, we help propel these companies to the exit and realize consistent performance for our investors.
We invest in companies consolidators want to buy: commercial-stage healthcare innovators with market-proven products supported by solid medical evidence, regulatory approvals, and a plan to exit within 5 years.
Each company and situation is unique. We provide customized financial structures to meet the needs of targeted companies while seeking the optimal risk/reward profile for our investors. Through creative deal structuring, we seek solid downside protection with potential for enhanced upside returns.
By actively guiding companies to the exit, we help investors get their money out sooner. We target consistent minimum returns across the portfolio with a shorter investment period and quicker distributions than typical funds.
We are healthcare veterans with decades of collective experience in operations, finance, private equity, venture capital and investment banking. Since April 2009 our team has established a successful strategy through collaboration on multiple funds.
SightLine is a vital partner to growth-stage healthcare companies. We bring the strategic funding and financial and operational guidance they need on their path to growth and exit. Our partners have served as buyers, sellers, board members and advisors to healthcare innovators in more than 200 successful deals.
Due to confidentiality agreements, we do not disclose the names of companies in which we invest. To learn about our portfolio, contact us.